• Equity PC Ratio   0.57
  • |
  • Index PC Ratio   1.14
  • |
  • Total PC Ratio   0.97
  • |
  • VIX PC Ratio   0.54
  • VIX 16.28
  • VXN 20.77
  • VXO 17.15
  • ISEE 85.00

TruCharts Trading Strategies and Stock Buy/Sell Reports
(Show Details)


Chart Settings
No saved settings found!

Chart Type:
From: / / To: / /
Show detail in :
 Chart Skins:      
Price Overlays:





Indicator Windows:





NO
Refresh      
()
Last Trade Dividend/Share PE Ratio
Date Dividend Yield Return on Assets
Change ExDividend Date Return on Capital
Bid Latest EPS Price/Sale
Ask LatestEPS Date Price to Book
Volume EPS ttm Institutional %
Avg Volume Shares Outstanding Insider %
Open Float Short Ratio
Prev Close Return On Equity 5 Year Change %
High Consensus EPS 2 Year Change %
Low No. of Estimate 1 Year Change %
52 Week High EPS Surprise $ YTD Change %
52 Week Low EPS Surprise Percent 6 Month Change %
52 Week Change EBITDA 3 Month Change %
50 Day MA Revenue 1 Month Change %
200 Day MA Gross Profit 5 Day Change %
Market Cap Cash 30 Day Change %
Beta Debt Stock Exchange
Sector Revenue Per Share Short Interest
Short Date Revenue Per Employee Short Ratio
Data courtesy of IEX
Company Profile

SIGA Technologies, Inc., a bio-defense company, engages in the discovery, development, and commercialization of products for use in defense against biological warfare agents comprising smallpox and arenaviruses. It also involves in the discovery and development of other novel anti-infectives and antibiotics for the prevention and treatment of serious infectious diseases. The company primarily offers ST-246, an orally administered antiviral drug that targets orthopox viruses. It also develops anti-arenavirus drug candidates, such as ST-294 and ST-193, which demonstrate antiviral activity in cell culture assays against arenavirus pathogens; and broad spectrum antiviral candidate, ST-669, against viruses in the Poxviridae, Filoviridae, Bunyaviridae, Arenaviridae, Flaviviridae, Togaviridae, Retroviridae, and Picornaviridae families. In addition, the company has four drug series in the pre-clinical development stage, including ST-610 and ST-148 for dengue virus of the genus Flavivirus. SIGA Technologies, Inc. was founded in 1995 and is headquartered in New York, New York.